Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based RegeneRx Biopharmaceuticals has received a Notice of Allowance for a second US patent for treating central nervous system injuries and disorders using Thymosin beta 4 (Tβ4) to regenerate damaged tissue.
Subscribe to our email newsletter
The company said that in this case, the patent will be for the treatment of patients suffering a stroke.
Researchers at the Henry Ford Hospital in Detroit, US, have found Tß4’s effects in animal studies carried out under a Material Transfer Agreement between the Institution and RegeneRx.
RegeneRx has got a license to the intellectual property and the patent will expire in 2026.
The company is focused on the development of a new therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration.
Currently, the company has three drug candidates under clinical development for ophthalmic, cardiac and dermal indications, three strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the EU, and has an extensive worldwide patent portfolio covering its products.
RegeneRx has also developed many peptides that it believes may be useful improving aging skin in the cosmeceutical field.